FDA Approves Novel Antibiotic Combination Emblaveo for Complex Abdominal Infections
Key Insights
AbbVie (search)'s Emblaveo, a groundbreaking aztreonam-avibactam combination, receives FDA approval for treating complicated intra-abdominal infections (search) with limited treatment options.
The novel therapy combines a monobactam antibiotic with a β-lactamase inhibitor, effectively targeting resistant Gram-negative bacteria including those producing metallo-β-lactamases.
Commercial availability is scheduled for Q3 2025, offering healthcare providers a crucial new tool against antimicrobial-resistant pathogens in complicated intra-abdominal infections (search).
AbbVie (search) has secured FDA approval for Emblaveo, a first-in-class combination antibiotic therapy that pairs aztreonam with avibactam, marking a significant advancement in the treatment of complicated intra-abdominal infections (search) (cIAI). The approval specifically targets adult patients with limited or no alternative treatment options.
Addressing Critical Treatment Gaps
The therapy, to be used in combination with metronidazole, demonstrates effectiveness against several challenging Gram-negative microorganisms, including Escherichia coli (search), Klebsiella pneumoniae (search), and Enterobacter cloacae (search) complex. This development comes at a crucial time when antimicrobial resistance (AMR) poses an increasingly urgent global public health threat.
"The continued evolution of antimicrobial resistance among Gram-negative bacteria has left some patients with little to no treatment options, resulting in extended hospital stays, additional morbidity and death," explains Dr. James A. McKinnell, an infectious disease specialist at Torrance Memorial Medical Center. "Emblaveo provides physicians a much-needed therapeutic option to help address some of the most difficult antimicrobial-resistant pathogens."
Innovative Mechanism of Action
The drug's effectiveness stems from its unique composition: aztreonam, a monobactam antibiotic, works in concert with avibactam, a β-lactamase inhibitor. This combination is particularly noteworthy as avibactam protects aztreonam from serine β-lactamase hydrolysis, restoring its activity against bacteria that produce both metallo-β-lactamases (MBLs) and serine β-lactamases.
Clinical Evidence and Approval Basis
The FDA's decision was supported by previous efficacy and safety data for aztreonam in cIAI treatment, alongside results from the Phase 3 REVISIT (search) study. This clinical trial demonstrated the combination's efficacy against serious infections caused by Gram-negative bacteria, including multidrug-resistant pathogens that produce MBLs.
Dr. Roopal Thakkar, AbbVie (search)'s executive vice president of research & development and chief scientific officer, emphasizes the collaborative nature of this achievement: "As bacteria evolve, industry, government, and clinical experts must work together to ensure that the infectious disease community has the tools to advance public health."
Market Availability and Implementation
Healthcare providers and patients can expect Emblaveo to become commercially available in the United States during the third quarter of 2025. This timeline allows for necessary preparation and integration into existing treatment protocols for complicated intra-abdominal infections (search).